The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention.
The shots, which are administered by a health care provider every two months, were more effective than daily PrEP pills in two large studies of gay men, trans women, and cisgender women. "The FDA approval of long-acting injectable cabotegravir is a major breakthrough for the prevention field," Dr.
Susan Buchbinder, director of Bridge HIV at the San Francisco Department of Public Health, said in a statement from the International AIDS Society. "Some people aren't able to, or don't want to, take PrEP pills.
Meaws.com provides you with the latest lgbt news worldwide. Gossips, photos and videos, exclusive interviews, breaking news from the rainbow world of queer people are waiting for you here. So, stay tuned and get to know who, where, when and with whom in the world of lgbt, happy and proud people. Are you eager to know first!? Then just follow us every day and we will offer you more and more!
Owner: SNOWLAND s.r.o.
Registration certificate 06691200
16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6
©2022. All rights reserved.